Rare Anaemias, Sickle-Cell Disease and COVID-19
Main Article Content
Keywords
.
Abstract
For rare haematological diseases (RHD), the first question to be answered is if patients with be- nign red blood cell (RBC) defects like haemoglobinopathies, membranopathies and enzymopathies are more vulnerable to COVID-19 infection. Up to now, there is no yet literature on the subject, but, like in general population, the presence of comorbidities such as diabetes, heart disease, pulmonary hypertension, reduced kidney and/or liver function, worsen the effects of the infection. Splenectomy may be an additional risk factor.
Downloads
References
2. European Commission. Health and Food Safety Directorate General. “COVID.19 Clinical Management Support System”. e-News. 27/03/2020. https://www.vml.org/enews-march-27-2020/.
3. COVID-19 and Rare Diseases. Orphanews 27 of March 2020. https://www.drroyspencer.com/2020/03/covid-19-deaths-in-europe-excess-mortality-is-down/.
4. COVID-19 and Rare Hematological Diseases. EuroBloodNet https://eurobloodnet.eu/covid-19/.
5.Thalassemia International Federation .The COVID–19 pandemic and haemoglobin disorders. A contribution of Thalassaemia International Federation to its global patients’ community.
https://thalassaemia.org.cy/publications/tif-publications/a-tif-proposed-haemoglobinopathy-patient-pathway-during-the-covid-19-pandemic-2.
6. . Haemoglobinopathy Co-ordinating Centres. https://www.england.nhs.uk/commissioning/spec-services/npc-crg/blood-and-infection-group-f/f05/.
Article Sidebar
Article Details
How to Cite
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.